Company Background
GondolaBio is a collection of biopharmaceutical companies focused on developing next-generation therapeutics for genetic diseases. Originally carved out of BridgeBio, GondolaBio secured $300M in private financing from external investors in 2024 and became an independent company within the BridgeBio ecosystem. GondolaBio aims to leverage cutting-edge biological research to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases.
Portal Therapeutics is an early clinical stage biotechnology company, and the lead program in GondolaBio’s portfolio. Portal is developing a novel potential best-in-class therapy for erythropoietic protoporphyria, a severe genetic disease of the blood which results in extreme sensitivity to sunlight and liver damage.
To learn more, visit us at gondolabio.com
Who You Are
The Director, Medical Science is responsible for building and leading field-based medical engagement in the Portal program in Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP). Reporting to the CMO and managing direct report(s), the Director executes medical affairs field strategy in alignment with business priorities and delivers high-quality, compliant scientific engagement with identified healthcare professionals (HCPs).
This is a field- and execution-focused leadership role. Working with leadership, the Director establishes and implements the Medical Affairs field plan, develops field-facing materials, and uses insights from the field to refine the plan over time.
The ideal candidate will have spent time as a Medical Science Liaison with a strong track record leading field execution with progressive managerial responsibility. Experience with a fast-moving rare-disease program is highly desirable.
Job details are sourced from the employer's original posting.
Open job postingAbout the company
This company is involved in clinical pharmacology and early clinical development, focusing on early clinical sciences and development strategy from first-in-human through Phase 2. They also lead quantitative sciences including data analytics, pharmacometrics, biostatistics, and data management to inform dose selection and program development.